Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

Cooper Hospital/UMDNJ-Robert Wood Johnson Medical School, Camden, NJ, USA.
AIDS (Impact Factor: 6.56). 06/2002; 16(8):1131-8. DOI: 10.1097/00002030-200205240-00006
Source: PubMed

ABSTRACT To determine the impact of HIV-1 drug resistance at baseline and antiretroviral drug levels (DL) during follow-up on virologic response to the next antiretroviral regimen.
Baseline genotypic and phenotypic susceptibility was obtained for plasma virus from patients failing a protease inhibitor-containing regimen. Untimed plasma antiretroviral DL were performed and the distribution of DL after 12 weeks of follow-up was classified as above (DLHigh) or below (DLLow) the median. Inhibitory quotients [IQ = (DL at week 12)/(fold change in IC50 to wild-type)] were determined for each drug in the regimen. Primary outcome was change in log10 plasma HIV-1 RNA viral load (DeltaVL) from baseline to 12 weeks.
There were 137 patients who had baseline resistance data available for the antiretroviral drugs used in the salvage regimen, and DL at week 12. Each drug with DLHigh was associated with DeltaVL = -0.40 (P = 0.0002) while each drug with DLLow had DeltaVL = -0.16 (P = 0.11). In multivariate models DeltaVL associated with each active drug (defined by genotype) with DLHigh was -0.48 log10 (P < 0.0001), and with each active drug with DLLow was -0.22 (P = 0.03). The DeltaVL was -0.18 if no drugs in the regimen had an IQ > median, compared to -0.58 for one drug, -1.06 for two drugs, -0.86 for three drugs, and -1.44 for four or five drugs with IQ > median (P < 0.0001 for trend).
In salvage therapy, both the number of active drugs and the DL for each drug in the new regimen determine the antiviral response.

  • Article: PharmAdapt
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: A randomized study to evaluate the usefulness of protease inhibitor (PI) therapeutic drug monitoring (TDM) in antiretroviral-experienced HIV-infected patients. Methods: In the control arm, treatment was modified according to genotypic resistance testing. In the TDM arm, therapy was modified on the basis of genotypic resistance testing and at week 8 according to PI plasma trough levels measured at week 4. The major endpoint was the change in HIV-RNA levels at week 12. Results: A total of 183 patients, 96 in the control arm and 87 in the TDM arm, were included in the study. Low-dose ritonavir to enhance the associated PI was prescribed to 62.5% of patients in the control arm and 65.5% of patients in the TDM arm. Using our PI concentration targets, 17/81 patients (21%) in the TDM arm were considered to have suboptimal or partly optimal PI plasma levels at week 4. Physician and protocol-driven PI modifications were performed in 18/85 patients (23.5%) in the TDM arm, and in seven of 94 patients (7%) in the control arm (P < 0.01). Week 12 HIV RNA dropped 2 log10 copies/ml in the control arm and 1.7 log10 copies/ml in the TDM arm, respectively. Conclusion: We found no statistically significant difference between the TDM arm and control arm in virological outcome at week 12. The utility of TDM could be dependent on the presence of low-dose ritonavir as a booster and the antiretroviral experience of the studied population. Effective non-toxic target concentrations for resistant viruses have still to be determined.
    AIDS 01/2002; 16(17):2311-2315. DOI:10.1097/00002030-200211220-00011 · 6.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The introduction of protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) has allowed for treatment of HIV-infected patients with 'highly active antiretroviral treatment' (HAART). The studies in this thesis aimed to optimize dosage regimens for PIs and NNRTIs by the assessment and interpretation of the pharmacokinetic characteristics of these agents.The thesis first presents a review of the literature on analytical methods for measurement of PIs in plasma, and a review of the practice of Therapeutic Drug Monitoring (TDM) for antiretroviral drugs. Subsequently an international interlaboratory quality control (QC) program was developed for measurement of antiretroviral drugs in plasma. The program revealed large variability in the ability of laboratories to measure PIs and NNRTIs accurately. By participating in the program, laboratories were alerted to previously unknown errors in their methods. A series of pharmacokinetic studies evaluated undesirable pharmacokinetic interactions between antiretroviral drugs, food and other drugs. One study revealed that indinavir/ritonavir (800/100 mg BID) should preferably be administered with food to reduce high, nephrotoxic peak plasma (Cmax) values of indinavir. Based on other studies it was concluded that the addition of efavirenz to indinavir/ritonavir (800/100 mg BID) results in significant decreases in plasma concentrations of indinavir. These decreases are not strong enough to warrant dose modifications of the indinavir/ritonavir combination in treatment-naïve HIV-infected patients. A low-dose of ritonavir (100 mg BID) appeared to exert a modest inhibitory effect on the activity of CYP2D6 in extensive metabolizers for CYP2D6. Finally, pharmacokinetic studies were performed that evaluated the interaction between PIs and low-dose ritonavir as a means to achieve once-daily dosing for PIs. It was assessed that both nelfinavir and indinavir can be combined with low-dose ritonavir to yield adequate trough (Cmin) levels during a once-daily 24-h dosing interval.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thin layer chromatography (TLC) can be used to perform therapeutic drug monitoring in resource-limited settings, where more expensive analytical methods, such as high-performance liquid chromatography or liquid chromatography-mass spectrometry, are not feasible. The aim of this cross-sectional study was to compare saliva concentrations of nevirapine (NVP) with self-reported adherence in patients on NVP-containing antiretroviral treatment at Kilimanjaro Christian Medical Centre, Moshi, Tanzania. HIV-infected patients using a combination of zidovudine + lamivudine + NVP, or stavudine + lamivudine + NVP, for more than 4 weeks were included. Saliva samples were collected using dental cotton rolls impregnated with citric acid (20 mg). Saliva NVP concentrations were analyzed using TLC. Adherence to ARV medication was assessed by self-reporting using the Morisky scale. Of the 91 study participants, 79 (86.8%) had therapeutic saliva NVP concentrations (ie, >1.75 mg/L) and 12 (13.2%) had subtherapeutic concentrations. Self-reported adherence among the study participants was high in 62 participants (68.1%), moderate in 24 (26.4%), and low in 5 (5.5%). Fifty-seven (91.9%) of the study participants with high self-reported adherence had therapeutic saliva NVP concentrations. Of the 5 participants with low self-reported adherence, 3 had therapeutic NVP concentrations. A high proportion of patients had therapeutic NVP saliva concentrations as measured by TLC, which showed a good agreement with self-reported adherence.
    Therapeutic drug monitoring 12/2013; DOI:10.1097/FTD.0000000000000005 · 1.93 Impact Factor